Who
Caley Castelein
Director
Company insider
Files Form 4 as: Director, Whitehawk Therapeutics; Director, Tourmaline Bio; Director and 10% owner, ViewRay; 10% owner, Neos Therapeutics.
In numbers
- Trades disclosed
- 74
- Buys
- 6
- Sells
- 1
- Bought
- $9.3M
- Sold
- $164K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 28 Jul 2015
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 15 Jun 2026 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,040 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,040 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | WHWK Whitehawk TherapeuticsBiotechnology | SEC FORM 4 Code A | $1000K255,102 at $3.92 | filing |
| 14 May 2026filed 18 May 2026 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $16.84T2,072,756 at $8,124,996.24 | filing |
| 14 May 2026filed 18 May 2026 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $16.84T2,072,756 at $8,124,996.24 | filing |
| 14 May 2026filed 18 May 2026 | WHWK Whitehawk TherapeuticsBiotechnology | SEC FORM 4 Code A | $1000K255,102 at $3.92 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —16,800 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Bio | SEC FORM 4 Code U | —515,997 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Bio | SEC FORM 4 Code U | —431,939 | filing |
| 15 Oct 2025filed 17 Oct 2025 | Tourmaline Bio | SEC FORM 4 Code G | —522 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,006 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code A | —16,800 at $0.00 | filing |
| 4 Mar 2025filed 4 Mar 2025 | WHWK Whitehawk TherapeuticsBiotechnology | SEC FORM 4 Code A | $4.0M1,666,000 at $2.40 | filing |
| 12 Jun 2024filed 14 Jun 2024 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,832 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Tourmaline Biooption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 27 Oct 2023filed 27 Oct 2023 | Tourmaline Bio | SEC FORM 4 Bought | $230K15,800 at $14.55 | filing |
| 25 Oct 2023filed 27 Oct 2023 | Tourmaline Bio | SEC FORM 4 Bought | $51K4,200 at $12.07 | filing |
| 23 Oct 2023filed 23 Oct 2023 | Tourmaline Biooption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
Financial Review: Whitehawk Therapeutics (NASDAQ:WHWK) and BeyondSpring (NASDAQ:BYSI)WHWK · dailypolitical.com · 17 Oct 2026Head to Head Analysis: Whitehawk Therapeutics (NASDAQ:WHWK) vs. Surrozen (NASDAQ:SRZN)WHWK · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Caley Castelein; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.